FluoroPharma Medical, Inc. (FPMI) Appoints Mr. Thijs Spoor as Chief Executive Officer and Director
FluoroPharma, an independent privately held biopharmaceutical company engaged in discovery and development of imaging radiopharmaceuticals for use in cardiology and Alzheimer's disease, announced today the appointment of Thijs Spoor as the new CEO in conjunction with his appointment to its Board of Directors. Mr. Spoor has 15 years of international experience in the medical industry across a variety of roles including Regulatory Affairs, New Product Development and as the Global Brand Head for Nuclear Cardiology at (Amersham) GE Healthcare and most recently as the CFO of Sunstone BioSciences. He also spent 4 years on Wall Street at J.P. Morgan and…